Glecaprevir + pibrentasvir for treatment of hepatitis C

Andres F. Carrion, Paul Martin

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Introduction: Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent antiviral activity against all hepatitis C virus (HCV) genotypes. This regimen offers a shorter course of therapy (8 weeks) for selected patients regardless of genotype and has demonstrated high virological efficacy for retreatment of individuals who previously failed an NS5A containing regimen. Glecaprevir and pibrentasvir are minimally excreted by the kidneys; thus this regimen can safely be used in individuals with severe chronic kidney disease (CKD), including those undergoing hemodialysis. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy, and safety profile of glecaprevir/pibrentasvir. It also covers key phase 2 and 3 clinical trials that led to licensure of this regimen. Expert opinion: Glecaprevir/pibrentasvir is the latest antiviral regimen licensed in the United States for treatment of HCV infection. Although several other direct-acting antiviral agents (DAAs) are currently available, glecaprevir/pibrentasvir has some unique characteristics that expand treatment options for HCV infection, including patients with comorbidities such as advanced stage CKD or prior treatment failure to antiviral regimens containing other DAAs.

Original languageEnglish (US)
Pages (from-to)413-419
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume19
Issue number4
DOIs
StatePublished - Mar 4 2018

Fingerprint

Hepatitis C
Antiviral Agents
Hepacivirus
Virus Diseases
Chronic Renal Insufficiency
Genotype
Therapeutics
Phase III Clinical Trials
Retreatment
Expert Testimony
Licensure
Treatment Failure
Renal Dialysis
Comorbidity
Pharmacokinetics
Kidney
Safety

Keywords

  • Antiviral therapy
  • direct-acting antiviral agents
  • hepatitis C
  • sustained virological response

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Glecaprevir + pibrentasvir for treatment of hepatitis C. / Carrion, Andres F.; Martin, Paul.

In: Expert Opinion on Pharmacotherapy, Vol. 19, No. 4, 04.03.2018, p. 413-419.

Research output: Contribution to journalReview article

@article{c21f15fac6704341afef834d32d10d09,
title = "Glecaprevir + pibrentasvir for treatment of hepatitis C",
abstract = "Introduction: Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent antiviral activity against all hepatitis C virus (HCV) genotypes. This regimen offers a shorter course of therapy (8 weeks) for selected patients regardless of genotype and has demonstrated high virological efficacy for retreatment of individuals who previously failed an NS5A containing regimen. Glecaprevir and pibrentasvir are minimally excreted by the kidneys; thus this regimen can safely be used in individuals with severe chronic kidney disease (CKD), including those undergoing hemodialysis. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy, and safety profile of glecaprevir/pibrentasvir. It also covers key phase 2 and 3 clinical trials that led to licensure of this regimen. Expert opinion: Glecaprevir/pibrentasvir is the latest antiviral regimen licensed in the United States for treatment of HCV infection. Although several other direct-acting antiviral agents (DAAs) are currently available, glecaprevir/pibrentasvir has some unique characteristics that expand treatment options for HCV infection, including patients with comorbidities such as advanced stage CKD or prior treatment failure to antiviral regimens containing other DAAs.",
keywords = "Antiviral therapy, direct-acting antiviral agents, hepatitis C, sustained virological response",
author = "Carrion, {Andres F.} and Paul Martin",
year = "2018",
month = "3",
day = "4",
doi = "10.1080/14656566.2018.1444030",
language = "English (US)",
volume = "19",
pages = "413--419",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Glecaprevir + pibrentasvir for treatment of hepatitis C

AU - Carrion, Andres F.

AU - Martin, Paul

PY - 2018/3/4

Y1 - 2018/3/4

N2 - Introduction: Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent antiviral activity against all hepatitis C virus (HCV) genotypes. This regimen offers a shorter course of therapy (8 weeks) for selected patients regardless of genotype and has demonstrated high virological efficacy for retreatment of individuals who previously failed an NS5A containing regimen. Glecaprevir and pibrentasvir are minimally excreted by the kidneys; thus this regimen can safely be used in individuals with severe chronic kidney disease (CKD), including those undergoing hemodialysis. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy, and safety profile of glecaprevir/pibrentasvir. It also covers key phase 2 and 3 clinical trials that led to licensure of this regimen. Expert opinion: Glecaprevir/pibrentasvir is the latest antiviral regimen licensed in the United States for treatment of HCV infection. Although several other direct-acting antiviral agents (DAAs) are currently available, glecaprevir/pibrentasvir has some unique characteristics that expand treatment options for HCV infection, including patients with comorbidities such as advanced stage CKD or prior treatment failure to antiviral regimens containing other DAAs.

AB - Introduction: Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent antiviral activity against all hepatitis C virus (HCV) genotypes. This regimen offers a shorter course of therapy (8 weeks) for selected patients regardless of genotype and has demonstrated high virological efficacy for retreatment of individuals who previously failed an NS5A containing regimen. Glecaprevir and pibrentasvir are minimally excreted by the kidneys; thus this regimen can safely be used in individuals with severe chronic kidney disease (CKD), including those undergoing hemodialysis. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy, and safety profile of glecaprevir/pibrentasvir. It also covers key phase 2 and 3 clinical trials that led to licensure of this regimen. Expert opinion: Glecaprevir/pibrentasvir is the latest antiviral regimen licensed in the United States for treatment of HCV infection. Although several other direct-acting antiviral agents (DAAs) are currently available, glecaprevir/pibrentasvir has some unique characteristics that expand treatment options for HCV infection, including patients with comorbidities such as advanced stage CKD or prior treatment failure to antiviral regimens containing other DAAs.

KW - Antiviral therapy

KW - direct-acting antiviral agents

KW - hepatitis C

KW - sustained virological response

UR - http://www.scopus.com/inward/record.url?scp=85043309253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043309253&partnerID=8YFLogxK

U2 - 10.1080/14656566.2018.1444030

DO - 10.1080/14656566.2018.1444030

M3 - Review article

C2 - 29465262

AN - SCOPUS:85043309253

VL - 19

SP - 413

EP - 419

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 4

ER -